- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.12.25 | EC approves Incyte's Minjuvi combo for follicular lymphoma | ||
| 18.12.25 | Alnylam plans $250m investment in Norton manufacturing facility, US | ||
| 17.12.25 | CDC ends universal newborn hepatitis B vaccine recommendations | ||
| 17.12.25 | GSK obtains FDA approval for Exdensur in severe asthma | ||
| 17.12.25 | Harbour BioMed and BMS sign multi-specific antibody collab | ||
| 17.12.25 | Precision medicine approaches needed in oncology to match evolving SoC | ||
| 17.12.25 | INCOG reveals $200m injectable drug expansion in Indiana | ||
| 16.12.25 | Sanofi signs pair of billion-dollar biotech deals to bolster pipeline | ||
| 16.12.25 | Pfizer trims 2026 profit forecast amid Covid headwinds and patent cliff pressures | ||
| 16.12.25 | LEO Pharma applies to EMA to expand Anzupgo use to adolescents | ||
| 16.12.25 | SK Capital Partners supports Swixx BioPharma's global expansion | ||
| 15.12.25 | J&J gains label expansion approval for Akeega in mCSPC | ||
| 15.12.25 | First gonorrhoea antibiotics in decades herald new era of treatment | ||
| 15.12.25 | Sanofi shares fall 6% after double setback for MS drug tolebrutinib | ||
| 15.12.25 | FDA approves Acadia's Daybue Stix for Rett syndrome | ||
| 15.12.25 | Sobi buys Arthrosi to expand gout treatment pipeline | ||
| 12.12.25 | EU inches closer to new pharma legislation amid competitiveness drive | ||
| 12.12.25 | China's NMPA approves Sanofi's rare haematologic disease treatments | ||
| 12.12.25 | Zealand Pharma and OTR to develop metabolic disease therapeutics | ||
| 11.12.25 | Novartis and UK-based Relation forge R&D deal worth up to $1.7bn | ||
| 11.12.25 | Moderna signs deal worth up to $503m with Nanexa | ||
| 11.12.25 | UK slashes 2026 drug rebate rate by one-third to win back pharma sentiments | ||
| 11.12.25 | Pfizer plans job cuts in Switzerland to reduce expenses | ||
| 11.12.25 | Boehringer's Jascayd gains China's NMPA approval for PPF | ||
| 11.12.25 | Formation Bio gains global rights to Lynk Pharma's TYK2 inhibitor |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .